Leerink Partnrs Has Bullish Forecast for Progyny Q2 Earnings

Progyny, Inc. (NASDAQ:PGNY - Free Report) - Equities research analysts at Leerink Partnrs upped their Q2 2025 EPS estimates for shares of Progyny in a note issued to investors on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.18 per share for the quarter, up from their previous estimate of $0.15. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Progyny's current full-year earnings is $0.60 per share. Leerink Partnrs also issued estimates for Progyny's Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.64 EPS.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.45 by ($0.28). The company had revenue of $324.04 million during the quarter, compared to the consensus estimate of $307.86 million. Progyny had a return on equity of 10.90% and a net margin of 4.33%. The firm's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share.

A number of other research firms also recently weighed in on PGNY. BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price on the stock in a research report on Monday, March 31st. Leerink Partners raised shares of Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price on the stock in a research report on Tuesday. Finally, Canaccord Genuity Group reduced their target price on shares of Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Progyny presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.09.

Progyny Price Performance

NASDAQ:PGNY opened at $23.61 on Friday. The firm's 50-day moving average price is $21.81 and its 200-day moving average price is $21.47. The company has a market capitalization of $2.02 billion, a PE ratio of 41.42, a P/E/G ratio of 2.50 and a beta of 1.31. Progyny has a 1-year low of $13.39 and a 1-year high of $30.42.

Insider Activity

In related news, Director Cheryl Scott sold 2,675 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the sale, the director directly owned 14,112 shares in the company, valued at approximately $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 9.40% of the company's stock.

Institutional Trading of Progyny

Large investors have recently added to or reduced their stakes in the business. Signaturefd LLC grew its position in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company's stock valued at $25,000 after buying an additional 1,355 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Progyny in the first quarter worth approximately $44,000. Militia Capital Partners LP boosted its position in shares of Progyny by 100.0% in the first quarter. Militia Capital Partners LP now owns 2,000 shares of the company's stock worth $45,000 after purchasing an additional 1,000 shares during the period. Brooklyn Investment Group boosted its position in shares of Progyny by 5,216.4% in the first quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after purchasing an additional 3,182 shares during the period. Finally, Natixis bought a new position in shares of Progyny in the fourth quarter worth approximately $69,000. 94.93% of the stock is currently owned by institutional investors.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.